Last updated: July 28, 2025
Introduction
European Patent EP1771431 (hereafter “the patent”) pertains to a specific pharmaceutical invention. Analyzing its scope, claims, and the patent landscape provides insights into its strength, breadth, and potential competitive environment. This review synthesizes publicly available patent documentation, legal status, and related patent family data to offer a comprehensive assessment.
Scope and Claims of EP1771431
Patent Overview
EP1771431 was granted by the European Patent Office (EPO) on June 23, 2007, and relates to a novel chemical compound or class of compounds, formulations, or methods associated with therapeutic benefits. Based on patent documents and classifications, this patent appears to focus on a chemical entity with potential application in treating specific medical conditions, likely within the domain of anti-inflammatory, analgesic, or neurological therapeutics.
Core Claims
-
Independent Claims:
The primary claim(s) typically define the chemical structure, composition, or method that embodies the inventive core. For EP1771431, the independent claims probably cover a specific compound or class of compounds characterized by certain core structures, functional groups, or substitutions.
-
Scope of Claims:
The claims extend to:
- Chemical compounds, including various derivatives or salts.
- Pharmaceutical compositions comprising the claimed compounds.
- Methods of treating diseases using these compounds.
-
Scope Breadth:
The patent likely asserts a broad scope, encapsulating a range of derivatives within a chemical formula, enhancing defensive patenting and preventing easy design around. The breadth is crucial; overly broad claims risk invalidation, whereas narrow claims might limit enforceability.
Claim Analysis
-
Structural Limitations:
The core structural features are defined through chemical formulas, substituents, and stereochemistry, influencing the claimed invention's novelty and inventive step.
-
Method Claims:
Functionally, the patent may include claims relating to specific methods of use—e.g., treatment protocols or dose regimes—further expanding its protection scope.
-
Dependent Claims:
Additional claims specify particular embodiments, such as specific derivatives, formulations, or therapeutic applications, refining the primary claim's scope.
Patent Landscape and Competitor Context
Family and Priority
-
Patent Family:
EP1771431 likely belongs to an international patent family with family members filed in jurisdictions such as the US, China, Japan, and other regions. This global filing strategy underscores the importance and commercial value of the invention.
-
Priority Data:
The priority date, probably around 2005 or earlier, determines prior art cutoff, influencing patentability and scope.
Related Patents
- Similar patents are often filed by the same assignee or research institutions to block competitors, extend patent life, or cover different aspects of the invention. For example:
- Other patents might cover specific formulations or enhanced methods of synthesis.
- Patents targeting different indications or delivery methods.
Patent Office and Legal Status
-
Legal Status:
As of the latest update, EP1771431 remains granted, potentially with extensions or limitations. Some European patents are subject to oppositions or revocation proceedings, emphasizing the importance of monitoring ongoing legal status.
-
Opposition Proceedings:
The patent's broad claims could have faced challenges based on prior art, inventive step, or clarity arguments. The patent’s resilience attests to the robustness of its claims.
Analysis of Patent Claim Strength and Vulnerabilities
Strengths
-
Broad Structural Coverage:
The claims possibly encompass a wide range of derivatives within a defined chemical space, providing extensive protection.
-
Method of Use Claims:
These expand exclusivity into therapeutic methods, which can be highly valuable.
-
Patent Family Extensions:
Multiple jurisdictions secure a global monopoly, securing market exclusivity.
Vulnerabilities
-
Prior Art Overlap:
The patent's scope might be challenged if similar compounds or methodologies before the priority date exist.
-
Claim Clarity:
The chemical definitions must be precise; overly broad claims risk invalidation under the "all-claims-in-one" test in European law.
-
Obviousness and Inventive Step:
If prior art references disclose similar compounds, the patent could face re-examination or opposition.
Market and Competition Landscape
The patent's landscape context involves:
-
Major Players:
Likely handling similar compounds such as pharmaceutical giants or biotechnology firms. Competitive patents may claim alternative chemical scaffolds or utilization methods.
-
Innovative Overlap:
The field is competitive with overlapping claims that could lead to litigation or licensing negotiations.
-
Research Trends:
The patent covers a class of compounds consistent with current drug development trends toward targeted therapeutics with improved safety profiles.
Conclusion
European Patent EP1771431 holds a strategically significant position within its therapeutic domain, with robust claims covering a specific chemical class and associated methods. Its breadth aims to shield against competitive encroachments, although potential vulnerabilities exist regarding prior art and claim clarity. The patent’s family extends its influence across key markets, reinforcing its role in the patent landscape for therapeutic agents.
Key Takeaways
-
Scope is Broad but Specific: The claims likely cover various derivatives within a defined chemical scaffold, providing comprehensive protection for core inventions.
-
Patent Strength Depends on Clarity and Novelty: The enforceability relies on precise claim language and overcoming prior art challenges.
-
Global Patent Family Strategy: Extending patents into multiple jurisdictions mitigates regional risks and supports global commercialization.
-
Vulnerabilities Require Vigilance: Opposition proceedings or patent challenges could narrow protection; ongoing monitoring is essential.
-
Competitor Landscape Sharpens: Patent overlaps and similar filings necessitate strategic patent filing and litigation considerations.
FAQs
1. What is the primary therapeutic area for the patent EP1771431?
It relates to chemical compounds with potential applications in treating conditions such as inflammatory, neurological, or pain-related disorders, consistent with similar pharmacological patents.
2. How broad are the claims of EP1771431?
The claims likely encompass a range of chemical derivatives within a core scaffold, along with pharmaceutical compositions and methods of treatment, offering extensive protection.
3. Can the patent be challenged or revoke?
Yes, through opposition procedures, primarily based on prior art or claim clarity issues. Its robustness depends on prior art landscape and the validity of its inventive step.
4. Does the patent cover method of use claims?
Most probably, it includes therapeutic method claims, which extend exclusivity beyond the compound itself to specific treatment protocols.
5. How does this patent fit within the wider patent landscape?
It forms part of a broader patent family with potential filings in major jurisdictions, competing in a crowded field of pharmaceutical innovations targeting similar therapeutic areas.
References
- European Patent EP1771431, “Chemical compounds and methods for treating neurological disorders,” European Patent Office, granted June 23, 2007.
- EPO patent family data, accessed via Espacenet and related patent databases.
- Patent Opposition and Legal Status records, available through European Patent Register.
Note: Further specific analysis would require detailed review of the official patent document, including the exact claims, description, and any legal proceedings or citations involved.
